A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
van Ewijk R, Cleirec M, Herold N, le Deley MC, van Eijkelenburg N, Boudou-Rouquette P, Risbourg S, Strauss SJ, Palmerini E, Boye K, Kager L, Hecker-Nolting S, Marchais A, Gaspar N; FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials.
van Ewijk R, et al. Among authors: boudou rouquette p.
Cancer Treat Rev. 2023 Nov;120:102625. doi: 10.1016/j.ctrv.2023.102625. Epub 2023 Sep 15.
Cancer Treat Rev. 2023.
PMID: 37738712
Free article.
Review.